寡核苷酸
脊髓性肌萎缩
药代动力学
核酸酶
药效学
药品
药理学
化学
RNA剪接
生物
立体化学
治疗窗口
体内分布
计算生物学
组合化学
作者
Anastasia Lepikhina,Eva-Maria Manz,Lucia Yang,Mathilde Vincent,Erick E Nakagaki-Silva,Angel Santorelli,Ying Hsiu Liu,Krainer Adrian r.,Jonathan Hall
出处
期刊:Nucleic Acid Therapeutics
[Mary Ann Liebert, Inc.]
日期:2026-11-13
卷期号:: 21593337261502915-21593337261502915
标识
DOI:10.1177/21593337261502915
摘要
In the pharmaceutical industry, stereopure drugs are generally preferred over isomeric mixtures to reduce the risks of side effects and to simplify pharmacodynamics (PD) and pharmacokinetics (PK) properties. This reasoning applies equally to antisense oligonucleotides (ASOs). All current ASO drugs are modified to provide appropriate PK/PD properties. Among the modifications, phosphorothioate (PS) groups provide essential nuclease resistance and advantageous biodistribution properties. However, PS groups are chiral, with R p- and S p-centers that are challenging to incorporate stereoselectively during solid-phase synthesis, and thus current ASO drugs are diastereoisomeric mixtures. Here, we describe the synthesis of stereodefined variants of the approved drug nusinersen (Spinraza), a 2′- O -methoxyethyl-modified oligonucleotide that redirects splicing of SMN2 during treatment for spinal muscular atrophy (SMA). We found that a single 3′- S p linkage stabilizes nusinersen from degradation in mouse tissue homogenates. Although R p-nusinersen has higher target-binding affinity than S p-nusinersen, it is not more active than parent nusinersen in patient-derived cells. Finally, we show mixed results from comparing stereodefined nusinersen with parent nusinersen in a murine model of SMA. While our data do not provide definitive evidence for the superior performance of stereodefined nusinersen, we conclude that it is likely equally effective as its parent ASO, while bearing the pharmacological advantages of a single stereoisomer.
科研通智能强力驱动
Strongly Powered by AbleSci AI